指南与共识肝病

FIB-4与瞬时弹性成像之间的不一致程度:当前指南在普通人群队列中的应用

Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort.
指南 / 共识 · Clin Gastroenterol Hepatol · 2024-02-29

基于2017至2020年美国国家健康与营养调查数据,纳入3741名有FibroScan数据的成年人,按AGA/AASLD指南用FIB-4对代谢功能障碍相关脂肪性肝病(MASLD)肝纤维化风险分层,以FibroScan肝硬度值为结局,发现FIB-4将许多受试者错误分类为低风险或高风险,作者认为解读时需谨慎或考虑替代策略。

要点

  • FIB-4判为低风险的2776人中,10%经肝硬度值未判为低风险,2.7%被判为高风险。
  • FIB-4判为高风险的86人中,79.1%经肝硬度值未判为高风险,62.8%被判为低风险。
  • FIB-4错误分类为低风险的受试者年龄更大,体重指数、腰围、糖化血红蛋白A1c、丙氨酸转氨酶、天冬氨酸转氨酶等更高。

核心结论

  • 在AGA/AASLD指南中用FIB-4对MASLD相关纤维化风险人群进行风险分层,导致许多受试者被错误分类为低风险和高风险类别。
  • 因此,可能值得考虑在解读时保持谨慎和/或采用替代策略。

研究设计与样本

  • 使用2017至2020年美国国家健康与营养调查数据集,选取年龄≥18岁且有FibroScan数据的受试者。
  • 遵循AGA/AASLD指南识别具有MASLD相关肝纤维化风险的受试者,并排除其他肝病病因。
  • 最终队列共3741名受试者,按推荐的FIB-4截断值分类,以FibroScan肝硬度测量(LSM)作为结局测量。

主要发现

  • FIB-4分类为低风险的2776名受试者(74.2%)中,277名(10%)经LSM未分类为低风险,75名(2.7%)经LSM分类为高风险。
  • FIB-4分类为高风险的86名受试者中,68名(79.1%)经LSM未处于高风险,54名(62.8%)经LSM处于低风险。
  • 被FIB-4错误分类为低风险的受试者年龄更大,体重指数、腰围、糖化血红蛋白A1c水平、丙氨酸转氨酶、天冬氨酸转氨酶、舒张压、受控衰减参数评分、白细胞计数、碱性磷酸酶和空腹血糖水平更高,而高密度脂蛋白和白蛋白水平更低(所有P < .05)。
  • 被错误分类的受试者更可能患有糖尿病前期/糖尿病。

关键数值与推荐

  • FIB-4用于将MASLD相关纤维化风险患者分层为低风险、不确定风险或高风险,依据AGA/AASLD临床护理路径。
  • FIB-4分类为低风险者中10%经LSM未判为低风险,2.7%经LSM判为高风险。
  • FIB-4分类为高风险者中79.1%经LSM未判为高风险,62.8%经LSM判为低风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In the American Gastroenterological Association/American Association for the Study of Liver Diseases (AGA/AASLD) Clinical Care Pathway, Fibrosis-4 index (FIB-4) is used to stratify patients at risk for metabolic dysfunction-associated steatotic liver disease (MASLD) as low-, indeterminate-, or high-risk for developing advanced liver fibrosis. We assessed the performance of FIB-4 in a general population. METHODS: Using the 2017 to 2020 National Health and Nutrition Examination Surveys dataset, we selected subjects ≥18 years who had FibroScan data. We followed AGA/AASLD guidelines to identify subjects with characteristics that place them at risk for MASLD-associated liver fibrosis. Other causes of liver disease were excluded. Our final cohort had 3741 subjects. We then categorized these subjects based on recommended FIB-4 cutoffs. FibroScan liver stiffness measurement (LSM) served as the outcome measurement. RESULTS: Among the 2776 subjects (74.2%) classified as low risk by FIB-4, 277 subjects (10%) were not classified at low risk by LSM, and 75 subjects (2.7%) were classified as high risk by LSM. Among the 86 subjects classified as high risk by FIB-4, 68 subjects (79.1%) were not at high risk by LSM, and 54 subjects (62.8%) were at low risk by LSM. Subjects misclassified by FIB-4 as low risk were older; had a higher body mass index, waist circumference, glycohemoglobin A1c level, alanine transaminase, aspartate transaminase, diastolic blood pressure, controlled attenuation parameter score, white blood cell count, alkaline phosphatase, and fasting glucose level; but had lower high-density lipoprotein, and albumin level (all P < .05). Misclassified subjects were also more likely to have prediabetes/diabetes. CONCLUSION: Using FIB-4 in the AGA/AASLD guidelines to risk-stratify subjects at risk for MASLD-associated fibrosis results in many subjects being misclassified into the low- and high-risk categories. Therefore, it may be worthwhile considering caution in interpretation and/or alternative strategies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chang M, Chang D, Kodali S, et al. Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort. Clin Gastroenterol Hepatol. 2024. PMID: 38428706. doi:10.1016/j.cgh.2024.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。